Stock Analiz

ProQR Therapeutics N.V. PRQR

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$1.41Market cap $199M
Open the interactive analysis →

ProQR Therapeutics N.V. (PRQR) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to June 30, 2026 it had revenue of $20M and net income of -$46M, a net margin of -228.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -53%.

About ProQR Therapeutics

ProQR Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $2M in 2021 to $19M in 2025, growth of about 87.5% a year. It was profitable in 0 of the last 10 years in our data.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S9.8
P/B2.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-27.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-4.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1437.2%
ROIC (5-yr avg.)-52.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$20M$19M$20M$7M$4M$2M—————
Net income-$46M-$50M-$29M-$31M-$69M-$69M-$57M-$63M-$42M-$52M-$41M
Free cash flow-$55M-$63M-$39M$22M-$74M-$30M-$59M-$50M-$33M-$42M-$39M
EPS (diluted)$-0.44$-0.35$-0.20$-0.22$-0.49$-0.49$-0.40$-0.45$-0.30$-0.37$-0.29
Net margin-228.9%-265.2%-146.9%-431.7%-1792.5%-4549.8%—————
ROIC—-63.3%-32.5%-69.5%-69.7%-28.6%-45.0%-42.3%-28.0%-68.7%-53.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does ProQR Therapeutics pay a dividend?

Not currently.

Is ProQR Therapeutics a good stock to buy?

We do not give buy or sell advice. ProQR Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.